NeoPhore
PrivateLast Round
Series B
Extension
May 22, 2024
Total Funding Raised
$44.65M
Company Overview
NeoPhore is a biotechnology company focused on developing innovative small molecule therapies that harness the immune system to treat cancer by targeting genetic mechanisms to generate neoantigens, potentially enhancing clinical outcomes for patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeoPhore Comps
Public and private peers based on sector, stage, and business model.
NeoPhore Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 22, 2024 | ||||
| Series B Extension | Jan 19, 2023 | ||||
| Series B | Mar 9, 2021 | ||||
| Seed | Nov 15, 2017 |
Key People
Founding team and executive leadership
NeoPhore Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 3B FUTURE Health Fund | Series B, Series B Extension |
| Neva SGR | Series B Extension |
| Sixth Element Capital | Seed |
| Claris Ventures | Series B Extension, Series B |
| 2invest AG | Series B, Series B Extension |
| Simon Fiduciaria | Series B Extension |
| Astellas Venture Management | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2025
CEO presented at the Morgan Stanley Global Healthcare Conference on September 1, 2025.
- Jan 1, 2025
Partnering with Memorial Sloan Kettering Cancer Center via scientific founder Dr. Luis Diaz.
NeoPhore Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NeoPhore's valuation, stock price, and market status.
